Measuring the risk of torsades de pointes: Electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures

Journal of Pharmacological and Toxicological Methods

Volumn 60, Issue 1, 2009, Pages 51-57

  Bass, Alan S ^a   Hanson, Laurie A ^b   Jackson, Terry A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PFIZER INC   (United States)

Author keywords

Arrhythmia; Cardiac ventricular repolarization; Cardiovascular toxicity; ICH S7A and S7B; Non human primate; QT and QTc interval; Safety Pharmacology; Torsades de Pointes

Indexed keywords

PNU 142093; SEROTONIN 1D AGONIST; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG STRUCTURE; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; MALE; MONKEY; NONHUMAN; PRIMATE; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; SINGLE DRUG DOSE; STRESS; T WAVE; TELEMETRY; TORSADE DES POINTES; TOXICITY TESTING;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZOPYRANS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; HEART RATE; LONG QT SYNDROME; MACACA FASCICULARIS; PIPERAZINES; RECEPTORS, SEROTONIN, 5-HT1; RESTRAINT, PHYSICAL; RISK ASSESSMENT; TELEMETRY; TORSADES DE POINTES;

ANIMALIA; PRIMATES;

EID: 68549094244     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2009.05.003     Document Type: Article

References (27)

1. Anon. ICH guidance for industry S7A safety pharmacology studies for human pharmaceuticals (2001), U.S. Department of Health and Human Services, Food and Drug Administration, Washington, D.C., United States of America
2. Anon. ICH guidance for industry S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (2005), U.S. Department of Health and Human Services, Food and Drug Administration, Washington, D.C., United States of America
3. Anon. ICH Harmonized Tripartite Guideline E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Osaka May 2005b.
4. Ando K., Hombo T., Kanno A., Ikeda H., Imaizumi M., Shimizu N., et al. QT PRODACT: In vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. Journal of Pharmacological Sciences 99 (2005) 487-500
5. Authier S., Tanguay J.F., Fournier S., Gauvin D., Legaspi M., Chaurand F., et al. Conscious and anesthetized non-human primate safety pharmacology models: Hemodynamic sensitivity comparison. Journal of Pharmacological and Toxicological Methods 58 (2008) 94-98
6. Bass A.S., Cartwright M.E., Mahon C., Morrison R., Snyder R., McNamara P., et al. Exploratory Drug Safety: Combating attrition in discovery as a way of mitigating failure in development. Journal of Pharmacological and Toxicological Method 60 (2009) 69-78
7. Bass A.S., Darpo B., Breidenbach A., Bruse K., Feldman H.S., Garnes D., et al. International life sciences institute (health and environmental sciences institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes. British Journal of Pharmacology 154 (2008) 1491-1501
8. Bass A.S., Darpo B., Valentin J.P., Sager P., and Thomas K. Moving towards better predictors of drug-induced torsades de pointes. British Journal of Pharmacology 154 (2008) 1550-1553
9. Bass A.S., Siegl P.K., Gintant G., Murphy D.M., Porsolt R., and Siegl P. Current practices in safety pharmacology. In: Gad S.C. (Ed). Preclinical Development Handbook (2008), John Wiley & Sons, Inc 611-694
10. Chaves A.A., Keller W.J., O'Sullivan S., Williams M.A., Fitzgerald L.E., McPherson H.E., et al. Cardiovascular monkey telemetry: Sensitivity to detect QT interval prolongation. Journal of Pharmacological and Toxicological Methods 54 (2006) 150-158
11. Eckhardt L.L., Rajamani S., and January C.T. Protein trafficking abnormalities: A new mechanism in drug-induced long QT syndrome. British Journal of Pharmacology 145 (2005) 3-4
12. Fenichel R.R., Malik M., Antzelevitch C., Sanguinetti M., Roden D.M., Priori S.G., et al. Drug-induced torsades de pointes and implications for drug development. Journal of Cardiovascular Electrophysiology 15 (2004) 475-495
13. Fridericia L.S. Die Systolendauer in elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Medica Scandinavica 53 (1920) 469-486
14. Gintant G.A. Preclinical torsades-de-pointes screens: Advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacology & Therapeutics 119 (2008) 199-209
15. Guth, B.D., Bass, A.S., Briscoe, R., Markert, M., Siegl, P.K.S., Valentin, J.P., et al., in press. Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. Journal of Pharmacological and Toxicological Methods. doi:10.1016/j.vascn.2009.05.006.
16. Haushalter T.M., Friedrichs G.S., Reynolds D.L., Barecki-Roach M., Pastino G., Hayes R., et al. The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys. British Journal of Pharmacology 154 (2008) 1457-1464
17. Holzgrefe H.H., Cavero I., Buchanan L.V., Gill M.W., and Durham S.K. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: Effects of moxifloxacin. Journal of Pharmacological and Toxicological Methods 55 (2007) 227-237
18. Klumpp A., Trautmann T., Markert M., and Guth B. Optimizing the experimental environment for dog telemetry studies. Journal of Pharmacological & Toxicological Methods 54 (2006) 141-149
19. Lindgren S., Bass A.S., Briscoe R., Bruse K., Friedrichs G.S., Kallman M.J., et al. Benchmarking safety pharmacology regulatory packages and best practice. Journal of Pharmacological and Toxicological Methods 58 (2008) 99-109
20. Pregenzer J.F., Alberts G.L., Im W.B., Slightom J.L., Ennis M.D., Hoffman R.L., et al. Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands). British Journal of Pharmacology 127 (1999) 468-472
21. Roden D.M. Long QT syndrome: reduced repolarization reserve and the genetic link. Journal of Internal Medicine 259 (2006) 59-69
22. Roden D.M. Cellular basis of drug-induced torsades de pointes. British Journal of Pharmacology 154 (2008) 1502-1507
23. Sanguinetti M.C., Jiang C.G., Curran M.E., and Keating M.T. A mechanistic link between an inherited and an acquired cardiac-arrhythmia - Herg encodes the I-Kr potassium channel. Cell 81 (1995) 299-307
24. Sasaki H., Shimizu N., Suganami H., and Yamamoto K. QT PRODACT: Inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys. Journal of Pharmacological Sciences 99 (2005) 513-522
25. Shah R.R. Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance. Drug safety 30 (2007) 1093-1110
26. Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. British Journal of Pharmacology 154 (2008) 1528-1537
27. Thomsen M.B., Matz J., Volders P.G., and Vos M.A. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacology & Therapeutics 112 (2006) 150-170